Navigation Links
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Date:10/16/2009

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed entry of judgment in favor of NPC. NPC is pleased that the Alabama Supreme Court has found in our favor, which demonstrates that the State of Alabama's claims were unfounded. The State of Alabama had claimed that the prices provided by NPC to reporting services resulted in overpayment to pharmacists and doctors in the Alabama State Medicaid system, and a Montgomery County Circuit Court jury initially found NPC liable.

NPC was among 73 pharmaceutical manufacturers named in a lawsuit filed in 2005 by the Alabama Attorney General. Through the appeal process, NPC demonstrated that it reported true and accurate prices, based on terms that have been known and used by all participants in pharmaceuticals markets, including Alabama Medicaid, for more than 30 years.

"We're pleased by the Alabama Supreme Court's ruling today," said Ludwig Hantson, PhD, Head of Pharma North America, CEO, Novartis Pharmaceuticals Corporation. "NPC is committed to high ethical standards in the pricing, marketing and sale of all of our products."

NPC's mission is to help patients and provide access to medications that treat disease, ease suffering and improve people's lives. In 2008 alone, NPC provided approximately $4.1M in prescription drugs to over 2,100 low-income Alabamans through our Patient Assistance Program.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by express or implied discussions regarding the potential outcome of any other pricing litigation. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that NPC or its affiliates will be successful in any other pricing litigation against it. In particular, management's expectations could be affected by, among other things, the inherent unpredictability of the litigation process, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

    Novartis Media Relations

    Pam McKinlay                          Anna Frable
    Novartis Corporate Communications     Novartis Pharma Communications
    +1 212 830 2465 (direct)              +1 862 778 5388 (direct)
    +1 862 221 0151 (mobile)              +1 732 673 5262 (mobile)
    pamela.mckinlay@novartis.com          anna.frable@novartis.com

    e-mail: media.relations@novartis.com

SOURCE Novartis Pharmaceuticals Corporation


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... mixed colors as the NASDAQ Composite closed the trading ... 0.29% lower; and the S&P 500 was down 0.08%. ... of nine sectors finishing the day in green. Pre-market ... stocks: Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation ...
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn ... business channels. , While many results are clear, much of PR is hard to ... When it comes to measurement, firms should always take an all-inclusive approach that takes ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
(Date:3/28/2017)... Davis, California (PRWEB) , ... March 28, 2017 , ... Bacteria and fungi are probably ... all microorganisms are bad. In fact, including the right microorganisms in your diet can actually ... your favorite foods. , This is the topic of a new peer-reviewed paper ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... New patients ... to replace their missing teeth can now have them placed by Dr. Manju Kejriwal, ... latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant placement. ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of the ... Sudeep Roy, MD, was recently published in the American Journal of Cosmetic Surgery. “The ... Buckingham and Roy’s study on the use of Electro Lube during the facelift procedure. ...
Breaking Medicine News(10 mins):